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Abstract IgA nephropathy is the world’s most common
primary glomerulonephropathy. Recent evidence in a rat
model implicated excessive production of oxygen-free
radicals in the pathogenesis and suggested that vitamin
E-treatment ameliorated progression. We studied this an-
tioxidant therapy on the glomerular filtration rate (GFR),
proteinuria and hematuria in biopsy-proven IgA neph-
ropathy in children. The duration of treatment or placebo
was 2 years, with vitamin E treatment consisting of
400 IU/day in children weighing <30 kg, and twice that
dose for those >30 kg. We measured GFR at entry, mid-
point and exit. At baseline and at 4-month intervals after
randomization, urinary protein/creatinine ratios and uri-
nalysis were examined. The mixed model procedure with
log transformation was used in data analysis to test treat-
ment difference as well as the potential time effect. Fif-
ty-five patients were randomized and 38 completed at
least 1 year of follow-up. At entry, the clinical character-
istics were not different between the treatment and place-
bo groups. There was a trend toward better preservation
of GFR in vitamin E-treated versus placebo patients,
127±50 vs. 112±31 ml/min/1.73 m2, respectively
(P=0.09). The urinary protein/creatinine ratio was signif-
icantly lower in the vitamin E-treated group vs. placebo;
0.24±0.38 vs. 0.61±1.37 (P<0.013). However, there was
no difference in the prevalence of hematuria between the
groups. Vitamin E treatment in our study patients was as-
sociated with significantly lower proteinuria, but no ef-
fect on hematuria. While there was a trend toward stabi-
lization of GFR in the vitamin E-treated patients, long-
term treatment and follow-up are needed to determine
whether antioxidant therapy is associated with preserva-
tion of renal function in IgA nephropathy.
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Introduction
The end-stage renal disease program of chronic dialy-
sis/kidney transplantation costs the nation $15.64 bil-
lion/year [1]. IgA nephropathy accounts for 10–30% of
patients in end-stage renal failure [2, 3, 4, 5, 6]. The
long-term prognosis in children, previously presumed to
be less serious than in adults with this condition, has re-
cently been shown to be no different, with 25% of chil-
dren with biopsy-proven IgA nephropathy progressing to
end-stage renal disease in 20 years [7, 8].
The pathogenesis of IgA nephropathy is unclear [9,
10] and there are no proven therapies that reverse the
progressive glomerulosclerosis which leads to end-stage
kidney disease [11]. Recently, we documented increased
oxygen-free radical release in an experimental rat model
of IgA nephropathy [12]. Administration of a diet that
was modestly enriched in vitamin E ameliorated renal
functional deterioration and prevented glomerular dam-
age. This protective effect was associated with a de-
crease in renal cortical malondialdehyde content [12].
This demonstration that oxygen-free radical injury con-
tributes to the pathogenesis of IgA nephropathy and that
antioxidant therapy can decrease glomerular injury [12]
is in accordance with recent studies which indicate that
peripheral polymorphonuclear leukocytes isolated from
patients with IgA nephropathy generate increased
amounts of superoxide radicals [13, 14] and IgA-con-
taining immune-complexes stimulate production of oxy-
gen-free radicals by mesangial cells in situ [15]. In paral-
lel with enhanced superoxide production, aggregated
IgA induced Fcα receptor expression in leukocytes [13,
14]. These findings were correlated with the severity of
proteinuria in patients with IgA nephropathy [13, 14,
16].
We conducted a pilot study consisting of an intervent-
ional human trial using a randomized, placebo-controlled
prospective design in biopsy-proven IgA nephropathy
from a network of seven pediatric nephrology programs.
Materials and methods
Study subjects and procedures
This pilot study was prospective, double blinded and placebo con-
trolled. Institutional Review Board approval was obtained for each
of the seven participating pediatric nephrology programs. Patients
were approached by the investigator to participate in the study.
The purpose and procedures of the investigation were explained to
the parents or the legal guardian and to the child. Written informed
consent obtained from the parent or guardian, and where appropri-
ate from the child, was sent to the centralized Data Coordinating
Center (DCC). The DCC reviewed the signed consent form, clini-
cal record, and renal biopsy for entry into the study. Randomiza-
tion to placebo or treatment arms was generated by a computer to
achieve a balance between the two groups, so that baseline charac-
teristics of gender, ethnic group, height, weight, blood pressure
and geographic distribution were accounted for.
Primary IgA nephropathy, confirmed by the index renal biopsy
at the participating center with IgA deposition in the mesangium,
qualified for entry. Entry criteria also included patients with docu-
mented hematuria (more than three erythrocytes per high-power
field in spun urine sample) [17] on two occasions during the pre-
randomization period and a glomerular filtration rate between 20%
and 100% of normal for age. The choice of a lower limit of glom-
erular filtration rate lessened the likelihood of a patient exiting to
dialysis and/or transplantation during the period of the study. The
age of entry was less than 21 years of age.
The exclusion criteria were as follows: (1) secondary IgA
nephropathy associated with organ transplantation, HIV+, diabetes
mellitus, lupus nephritis, Alport syndrome, anaphylactoid purpura
nephropathy, chronic liver diseases (hepatitis, biliary tract obstruc-
tion), gastrointestinal diseases (celiac disease, Crohn disease, ade-
nocarcinoma), respiratory diseases (chronic obstructive bronchio-
litis, idiopathic interstitial pneumonia), dermatitis herpetiformis,
mycosis fungoidis, leprosy, episcleritis, anterior uveitis, ankyl-
osing spondylitis, relapsing polychondritis, schistosomiasis, Sjog-
ren syndrome, monoclonal IgA gammapathy and pregnancy; (2)
previous treatment with vitamin E, corticosteroid, cyclosporin, ta-
crolimus, warfarin, persantin, phenytoin, fish oil, omega 3-polyun-
saturated fatty acid, danazol, dapsone, dipyridamole, urokinase,
sodium cromoglycate, plasmaphoresis, angiotensin-converting en-
zyme inhibitor, tonsillectomy or Cordyceps sinensis (Chinese
herbal medicine); (3) pregnancy; and (4) hypertension, as defined
vide infra.
The exit criteria were: (1) dialysis/transplantation, as well as
hypertension (vide infra); (2) medical non-compliance (after two
consecutive warnings), documented by self-admission, medication
package counts, and serum vitamin E concentration; and (3) fail-
ure to report for two consecutive follow-up visits. The reasons for
exit were reported to the Data Coordinating Center and the Princi-
pal Investigator. Within reason, patients who exited the study con-
tinued to be followed.
The primary endpoints were changes in GFR and proteinuria
as indices of progression and response to therapy. The prevalence
of hematuria was a secondary endpoint.
Treatment
Patients received one or two placebos or vitamin E capsules,
which were identical in appearance. Children less than 30 kg body
weight received one capsule of 400 IU vitamin E/day; children of
30 kg body weight or above received two capsules of 400 IU/day.
Hoffman-La Roche Inc. provided both placebo and the vitamin E
capsules. These were enclosed in 30-day medication packages
(Remind-A-Pac, Southfield, MI) [18]. A back-up 1-month pack-
age was always made available for each patient at the respective
clinics.
Clinic visits and laboratory tests
At entry these parameters were obtained: height, weight, blood
pressure, physical examination, urinalysis of fresh early morning
specimen, and urine protein to creatinine ratio, 24-h creatinine
clearance, fasting serum electrolytes, urea nitrogen, creatinine and
vitamin E.
Hypertension was defined by diastolic blood pressure exceed-
ing the 95th percentile above normal for age documented on three
occasions in a quiet and relaxed setting. Hypertension or the use
of an antihypertensive medication was cause for exclusion or exit.
All exited patients continued as per this protocol, but their data
were separately analyzed.
At follow-up every 4 months, these parameters were obtained:
height, weight, blood pressure, physical examination, early morn-
ing urine protein/creatinine, urinalysis, serum electrolytes, urea ni-
trogen, creatinine and vitamin E. At annual intervals or study exit
24-h creatinine clearance was repeated.
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Microscopic urinalysis
The early morning, “clean catch” or clean-void and mid-stream
sample was the specimen of choice [17]. The analysis was done by
the investigator at the participating center. After mixing the fresh
specimen, 10–15 ml of urine was centrifuged at 2000 rpm for
5 min. The supernatant fluid was poured off and the resuspended
sediment mixed. A drop of sediment on a clean slide was prepared
for microscopic examination in subdued light [17]. The number of
red cells per high-power field was counted and reported. Red
cells, dysmorphic red cells, red cell casts and other elements [17]
were recorded.
Routine chemistry methods for urinalysis, urine protein 
and creatinine clearances
Routine laboratory procedures for dipstick urinalysis, protein and
creatinine of an early morning voiding were performed at the par-
ticipating centers. The standard 24-h creatinine clearances for
glomerular filtration rate were determined [19, 20].
Serum vitamin E concentration
Serum vitamin E concentration was determined as an index of
compliance, using the high-pressure liquid chromatography
(HPLC) method [21]. Specimens for vitamin E concentrations
were obtained at the participating centers and sent to the DCC for
analysis.
Statistical methods
The biostatistician was blinded to the treatment code, which was
not broken until data analysis was completed. The urinary protein
to creatinine ratio was analyzed by the mixed model procedure
[22]. The analysis was based on the log transformation of the ratio
[23] and both the treatment difference and the potential time ef-
fects were examined.
In analyzing the prevalence of hematuria, two approaches were
used: (1) either heme positive or heme negative on a dipstick of a
fresh urine sample or (2) positive or negative for three or more red
blood cells per high-power field in a fresh urine sample. The chi-
square test was used to test the differences between the placebo
and treatment arms.
The creatinine clearances were analyzed by Student’s t-test
[23] based on the log transformed data.
Results
From 1 January 1997 to 1 August 2000, 62 patients with
IgA nephropathy were evaluated and 55 who met the en-
try and exclusion criteria consented to enroll in the
study. Twenty-eight were randomized to receive placebo
and 27 received vitamin E.
Baseline characteristics
The clinical and laboratory characteristics of the two
groups were similar at randomization (Table 1) in terms
of gender, ethnic group, height, weight, blood pressure,
prevalence of hematuria, degree of proteinuria and creat-
inine clearance.
Study outcome
The serum α-tocopherol concentration increased signif-
icantly (P<0.001) from 0.84±0.25 mg/dl (mean ± SD)
in the placebo patients to 1.85±0.77 in the treated pa-
tients. The creatinine clearances at the end of the study
showed values of 112±31 ml/min/1.73 m2 in the place-
bo versus values of 127±50 ml/min/1.73 m2 in the treat-
ed patients (P=0.09). None suffered a significant de-
cline in GFR.
The data showed that there was no difference in the
prevalence of hematuria, either tested by +heme reaction
on dipstick or by red blood cells per high-power field.
The urinary protein to creatinine ratio showed a signifi-
cant drop (P=0.013) from the placebo group
(0.61±1.37 mg/mg) to the values in the treated group
(0.24±0.38 mg/mg).
No patients exited the study to end-stage kidney dis-
ease, dialysis or transplantation. Patients dropped out of
the study due to self-administration of vitamin E and
failure to keep two consecutive follow-up clinic appoint-
ments.
Safety
There were no complaints or untoward complications
from either group of patients.
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Table 1 Baseline characteristics at randomization (means ± SD)
(RBC/HPF red blood cell per high-power field)
Treatment Placebo 
(n) (%) (n) (%)
Male 21 (75) 19 (70)
Female 7 (25) 8 (30)
Race or ethnic group
Asian 3 (11) 1 (4)
Black 1 (4) 2 (7)
Other 1 (4) 0
White 23 (82) 24 (89)
Age (years) 11±4 12±3
Height (cm) 141±47 146±36
Weight (kg) 58±21 54±23
Blood pressure
Systolic (mmHg) 118±13 119±17
Diastolic (mmHg) 69±10 67±14
Hematuria
Dipstick + 25 (89) 22 (81)
>3 RBC/HPF 15 (54) 21 (78)
<3 RBC/HPF 4 (14) 3 (11)
Not done 9 (32) 3 (11)
Proteinuria
Dipstick + 23 (82) 23 (85)
Dipstick − 5 (17) 4 (15)
Protein/creatinine (mg/mg) 0.31±0.73 0.52±1.67
Creatinine clearance (ml/min/1.73 m2) 116±32 106±38
Discussion
In this investigator-initiated and NIH-funded pilot study,
vitamin E therapy was associated with a significant re-
duction in the proteinuria of children with biopsy-proven
IgA nephropathy, but with no significant changes in the
prevalence of hematuria. The results raise the possibility
of a renoprotective effect of vitamin E in IgA nephropa-
thy.
In a recent study, Chitalia et al. [24] showed that spot
urine protein to creatinine ratio (between 0.26 and
3.20 mg/mg) agrees closely with 24-h urine protein
along a wide range of renal function and glomerular dis-
eases. Their study [24] strengthens the validity of our us-
ing early morning, spot urine protein to creatinine ratio.
Our pilot data, therefore, support the promise of a full-
scale trial to test the efficacy of antioxidants in long-term
treatment of IgA nephropathy, including a focus on uri-
nary microalbuminuria [25] and new molecular biomark-
ers, e.g., urinary nephrin genes [26], as indices of renal
injury or recovery.
The difficulty in using an antioxidant, e.g., vitamin E,
in clinical trials lies in the fact that patients often want to
self-administer this over the counter, inexpensive prod-
uct, with no clinically relevant side effects. However, the
significantly low serum α-tocopherol concentrations in
the placebo patients compared to the higher values in the
treated patients attest to patient compliance. It is a credit
to the patients’ families and the bond with the clinical in-
vestigators that medical compliance was excellent
throughout the study.
In experimental IgA nephropathy, Trachtman et al.
[12] demonstrated that vitamin E treatment was associat-
ed with a significant reduction of proteinuria, as we now
confirm in this pilot study. In contrast to the unchanged
prevalence of hematuria in our human study, the animal
studies of Trachtman et al. [12] showed a significant re-
duction in the incidence of hematuria. Whether doubling
or tripling of the current dose of vitamin E might have an
effect on the prevalence of hematuria is conjectural. A
dose response study, similar to that conducted in experi-
mental IgA nephropathy [27], is outside the purview of
our study aim. A dose response study will require a larg-
er consortium of centers to provide the requisite number
of patients.
Similar to our TGFβ1 data for our rat model of IgA
nephropathy [12], increased glomerular TGFβ1 mRNA
in patients with IgA nephropathy has been demonstrated
by Naka et al. [16]. The progression of IgA nephropathy
may result from overexpression of TGFβ1 leading to
mesangial matrix expansion, interstitial fibrosis, and glo-
merulosclerosis. We hypothesize that the interception of
autocrine activation of TGFβ1 by the natural antioxidant,
vitamin E, may check disease progression in IgA neph-
ropathy [12].
Finally, creatinine clearance remained well preserved
in both placebo and treated groups. However, the esti-
mate of GFR used in this study may not be sensitive
enough to detect loss of renal function over the relatively
short duration of observation of our trial [26]. For IgA
nephropathy, a slowly progressive disease where
25–30% of patients continue over a quarter century to
end-stage renal disease [2, 3, 4], a full-scale, longer du-
ration clinical trial with more accurate measurement of
glomerular filtration rate [28] will be needed for valid
generalization.
It should be noted that the disease in our patients was
in the early and mild stages. There is a need to extend
these findings to more severely affected patients with
IgA nephropathy and to follow such patients for an ex-
tended period of time.
The data of the present pilot study were not designed
to test this question but may lead to the use of vitamin E
either alone or as an adjunct medication in early IgA
nephropathy to slow the rate of progression of this com-
mon primary glomerular disease.
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